12:00 AM
 | 
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BHR-100: Phase III ongoing

Besins' BHR Pharma LLC subsidiary said a DSMB recommended continuation of the double-blind, placebo-controlled, international Phase III SyNAPSe trial of BHR-100 based on safety data from 803 patients. Based on an interim analysis of the primary efficacy endpoint in 400 patients, the DSMB also concluded that there was...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >